CASBF OTC
CanSino Biologics Inc.
1W: +57.6%
1M: +1.1%
3M: +78.8%
YTD: -1.9%
1Y: -29.6%
3Y: +3.3%
5Y: -88.2%
$4.65
+1.70 (+57.73%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$169M
+81.6% ▲
Capital Expenditures
$458M
+25.0% ▲
5Y CAGR: +31.4%
Free Cash Flow
-$626M
+59.0% ▲
Dividends Paid
$64M
-1658.0% ▼
Buybacks
$7M
+0.0% ▲
Net Change in Cash
-$490M
+63.6% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$407M | $1.9B | -$1.2B | -$2.0B | -$381M |
| Depreciation & Amort. | $32M | $89M | $196M | $269M | $211M |
| Stock-Based Comp. | $18M | $10M | $10M | $10M | $3M |
| Change in Working Capital | -$101M | $84M | -$1.5B | -$157M | -$116M |
| Other Non-Cash Items | -$3M | -$32M | -$200M | $960M | $114M |
| Operating Cash Flow | -$469M | $2.0B | -$1.9B | -$908M | -$169M |
| — Investing Activities — | |||||
| Capital Expenditures | -$271M | -$1.2B | -$1.1B | -$610M | -$357M |
| Acquisitions (Net) | -$886K | -$65M | -$3M | -$337K | -$31M |
| Investment Purchases | -$6.3B | -$8.5B | -$12.4B | -$8.1B | -$12.9B |
| Investment Sales | $6.3B | $7.1B | $12.2B | $8.3B | $13.4B |
| Other Investing | $120M | $94M | $36M | -$48M | -$105M |
| Investing Cash Flow | -$183M | -$2.5B | -$1.2B | -$450M | $4M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$22M | $990M | $1.3B | $69M | -$260M |
| Stock Repurchased | $0 | $0 | -$150M | $0 | -$7M |
| Dividends Paid | -$7M | -$14M | -$194M | -$4M | -$64M |
| Other Financing | -$14M | $584M | -$70M | -$90M | -$10M |
| Financing Cash Flow | $4.9B | $1.6B | $855M | -$8M | -$334M |
| Net Change in Cash | $4.2B | $1.0B | -$2.1B | -$1.3B | -$490M |
| Cash End of Period | $4.4B | $5.5B | $3.4B | $2.0B | $1.6B |
| Free Cash Flow | -$740M | $811M | -$3.0B | -$1.5B | -$626M |